Aker BioMarine has signed a commercial agreement to develop several medical foods products based on the existing Lysoveta, with Trofi Nutritionals.
The research will target reproductive health and brain health, in addition to pre-natal supplements.
Matts Johansen, CEO at Aker BioMarine, said: "These diseases have a severe impact on the lives for a large proportion of the population globally. The collaboration with Trofi is an important milestone in commercialising Lysoveta and will continue to build the body of scientific evidence for Lysoveta's beneficial effects across life stages."
The latest science demonstrates that impairment of the MFSD2a transporter in certain diseases can result in DHA deficiency
According to the Centre for Disease Control and Prevention (CDC) there is an increase in these diseases in the US population. This is due to the fact that we are living longer with lifestyle related risk factors for these diseases. There are limited therapeutic options available in today's healthcare system to address these conditions.
Lysoveta features essential nutrients such as Choline, EPA and DHA in the form of Lysophosphatidylcholine (LPC). These nutrients have an important role in the development and function of the brain. LPC has shown to efficiently target the brain and demonstrated improvement in short-term memory in pre-clinical trials.
"The latest science demonstrates that impairment of the MFSD2a transporter in certain diseases can result in DHA deficiency. Therefore, we believe that utilising Lysoveta as a clinically validated medical food will be well accepted by the physician community" said co-founder Dr Michael Davidson.
The collaboration with Trofi is an important milestone in commercialising Lysoveta and will continue to build the body of scientific evidence for Lysoveta's beneficial effects across life stages.
"The Trofi Lysoveta based nutritional solutions will have the potential to improve the quality of life for millions of people," said Barbara McCartney CEO of Trofi Nutritionals.
Trofi is an early-stage pioneer in next-generation nutritional solutions designed to support a range of health needs from managing chronic conditions to achieving wellness goals.
The company was co-founded by Dr Michael Davidson, Clinical Professor of Medicine and Director of the Lipid Clinic at the University of Illinois, together with Jonathan Jonas, CEO of JVC investment Partners. Trofi is led by CEO Barbara McCartney, an accomplished multi-country leader in the nutrition and wellness space who has held business management roles with Nestle Health Science, Novartis Nutrition and Abbott Nutrition.
"The team at Trofi shares our understanding of the importance of Lysoveta based on the strong scientific foundation and preclinical data, substantiating their investment in clinical development," said Christine Strømhylden Lunder, Venture Lead for Lysoveta.
Under the agreement, Aker BioMarine will license, with associated royalties, relevant intellectual property rights and supply Lysoveta to Trofi, who will invest in clinical trials with the aim to develop and commercialise certain medical foods within the fields. Launch of first medical food and dietary supplement is planned for 2024.